Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
TORPEdO: IMPT not superior to IMRT in locally advanced oropharyngeal SCC, 12-mo G-tube/≥20% weight loss 18% vs 7% (p=0.079), UW-QoL 78.3 vs 77.1 (p=0.56).
Head-neck carried the day: phase 3 TORPEdO (N=205) showed no co-primary gain for IMPT over IMRT in locally advanced oropharyngeal SCC at 12 mo. The composite numerically favored IMRT (18% vs 7%, adj OR 2.80, p=0.079), driven by weight loss, not tubes. Proton delivery burden: 61% replanning, 49% of IMPT pts missed fractions.
read the full digest →Studies · 128
- TORPEdO18% vs 7% 12-mo G-tube dependence/≥20% weight loss (p=0.079), UW-QoL 78.3 vs 77.1 (p=0.56): IMPT not superior to IMRT, locally advanced oropharyngeal SCC.
- PROTEUS5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median f/u in a real-world high-risk prostate cancer benchmark cohort.
- MARCAP ConsortiumIPD meta-analysis, 10,853 pts: ADT added to RT improved MFS HR 0.83 and OS HR 0.86; dose escalation improved bRFS only.
- STAR-TREC12-mo TME-free survival 78.5% vs 60.6% (HR 1.90) favouring LCCRT over SCRT for organ preservation in mrT1-T3bN0 rectal cancer ≤40 mm.
- Focal Ablation vs IMRT Toxicity (SEER-Medicare)GI toxicity favored focal therapy at 24mo (11.0% vs 21.5%, OR 0.45) but GU toxicity favored IMRT (41.7% vs 29.3%, OR 1.69).
- NRG-GU0053yr DFS 88.6% SBRT vs 92.1% MH-IMRT, superiority rejected (adjusted HR 1.40, 0.91-2.13); bowel and GU toxicity favored SBRT.
- Testosterone recovery post-ADT discontinuation (podcast review)Review of two datasets: 25% of real-world pts recovered T within 12mo; 54% relugolix vs 3% leuprolide at 90d in HERO.
- Moderately hypofractionated partial breast reirradiation40Gy/15fx PBI re-RT after second lumpectomy: 3yr LR-FS, DR-FS and OS all 86%, no grade 3+ late events (N=11).
- NSABP B-35 margin-width analysis10yr IBTR 5.6% vs 4.0% at 1mm cutoff (abs diff 1.6%), 5.3% vs 3.8% at 2mm (abs diff 1.5%).
- Cardiac Risk After Heart-Sparing Breast RadiotherapyMax LAD ≥12 Gy EQD2: sHR 1.81 (1.04-3.16) for cardiac events; mean heart dose ≥2 Gy null (P=.99), 2223 left-sided pts.
- Organs at Risk Radiation Dose Constraints: 2025 UpdateSFRO 2025 OAR dose-constraint update: normofractionated, moderate hypofractionated and ablative tables across skull base, H&N, lung, breast, oesophagus, liver.
- HERO90-day testosterone recovery to ≥280 ng/dL 53.9% with relugolix vs 3.2% with leuprolide after 48wk ADT.